{"denoms":[{"counts":[{"groupId":"BG000","value":"5"}],"units":"Participants"}],"groups":[{"description":"CONDITIONING REGIMEN: Patients receive fludarabine IV over 2 hours on days -4, -3, and -2. Patients undergo TBI on day 0.\n\nTRANSPLANTATION: After completion of TBI, patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2 to 3 times daily on days -3 to 99 with taper beginning on day 100 and continuing until day 177 in the absence of GVHD. Beginning within 6 hours after transplantation, patients also receive mycophenolate mofetil IV or PO 3 times daily on days 0 to 40 followed by a taper in the absence of GVHD.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nperipheral blood stem cell transplantation: Undergo allogeneic bone marrow or peripheral blood stem cell transplantation\n\ncyclosporine: Given IV or PO\n\nmycophenolate mofetil: Given IV or PO\n\nlaboratory biomarker analysis: Correlative studies","id":"BG000","title":"Treatment (Allogeneic Hematopoietic Stem Cell Transplantation)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"33","upperLimit":"53","value":"43"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}